Muñoz Vendrell, AlbertTena Cucala, RaquelCampoy Diaz, SergioGarcía Parra, BeliaPrat, JoanMartínez Yélamos, SergioHuerta Villanueva, Mariano2023-05-292023-05-292023-04-011526-4610https://hdl.handle.net/2445/198616Background and Objectives First-line treatment for trigeminal neuralgia (TN) is limited to carbamazepine and oxcarbazepine, and in refractory cases, alternatives are scarce. Lacosamide has been suggested as a valid option. In this study, we describe a series of patients who received oral lacosamide as treatment for TN after first-line drug failure.Methods In this retrospective descriptive cohort study, we included patients with refractory TN who attended a tertiary center between 2015 and 2021 and were prescribed oral lacosamide after first-line treatment failure. The primary endpoints were pain relief and adverse effects. We secondarily analyzed clinical outcomes and compared responders versus nonresponders in the search for potential predictors of response.Results Eighty-six patients were included (mean age: 62 [SD 15.6] years; 54/86 [63%] female). The TN etiology was secondary in 16/86 (19%) patients. Concomitant continuous pain was present in 29/86 (34%) patients. The mean number of previous treatments was 2.7 [SD 1.5]. Pain relief was achieved in 57/86 (66%) cases, with 28/86 (33%) patients presenting adverse effects, all of which were mild. No statistically significant differences were observed between responders and nonresponders, but subtle clinical differences suggested potential predictors of response.Conclusion Lacosamide may be an effective and relatively safe treatment for refractory pain in TN patients after first-line treatment failure.6 p.application/pdfengcc by-nc-nd (c) Muñoz Vendrell, Albert et al., 2023http://creativecommons.org/licenses/by-nc-nd/3.0/es/Neuràlgia del trigeminTractament del dolorTrigeminal neuralgiaPain treatmentinfo:eu-repo/semantics/article2023-05-05info:eu-repo/semantics/openAccess37036126